The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies

Research output: Contribution to journal › Journal article › Research › peer-review

Standard

The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies. / Jensen, Benjamin Anderschou Holbech; Pedersen, Sara Ram; Christensen, Jan Pravsgaard; Thomsen, Allan Randrup.

In: P L o S One, Vol. 8, No. 6, e66081, 2013.

Research output: Contribution to journal › Journal article › Research › peer-review

Harvard

Jensen, BAH, Pedersen, SR, Christensen, JP & Thomsen, AR 2013, 'The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies', P L o S One, vol. 8, no. 6, e66081. https://doi.org/10.1371/journal.pone.0066081

APA

Jensen, B. A. H., Pedersen, S. R., Christensen, J. P., & Thomsen, A. R. (2013). The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies. P L o S One, 8(6), [e66081]. https://doi.org/10.1371/journal.pone.0066081

Vancouver

Jensen BAH, Pedersen SR, Christensen JP, Thomsen AR. The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies. P L o S One. 2013;8(6). e66081. https://doi.org/10.1371/journal.pone.0066081

Author

Jensen, Benjamin Anderschou Holbech ; Pedersen, Sara Ram ; Christensen, Jan Pravsgaard ; Thomsen, Allan Randrup. / The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies. In: P L o S One. 2013 ; Vol. 8, No. 6.

Bibtex

@article{dc4f3513c95a4447ad18edc136707c68,
title = "The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies",
abstract = "It has previously been found that combination therapy with anti-CTLA-4 and anti-4-1BB antibodies may enhance tumor immunity. However, this treatment is not efficient against all tumors, and it has been suggested that variations in tumor control may reflect differences in the immunogenicity of different tumors. In the present report, we have formally tested this hypothesis. Comparing the efficiency of combination antibody therapy against two antigenically distinct variants of the B16.F10 melanoma cell line, we observed that antibody therapy delayed the growth of a variant expressing an exogenous antigen (P",
author = "Jensen, {Benjamin Anderschou Holbech} and Pedersen, {Sara Ram} and Christensen, {Jan Pravsgaard} and Thomsen, {Allan Randrup}",
year = "2013",
doi = "10.1371/journal.pone.0066081",
language = "English",
volume = "8",
journal = "PLoS ONE",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "6",

}

RIS

TY - JOUR

T1 - The availability of a functional tumor targeting T-cell repertoire determines the anti-tumor efficiency of combination therapy with anti-CTLA-4 and anti-4-1BB antibodies

AU - Jensen, Benjamin Anderschou Holbech

AU - Pedersen, Sara Ram

AU - Christensen, Jan Pravsgaard

AU - Thomsen, Allan Randrup

PY - 2013

Y1 - 2013

N2 - It has previously been found that combination therapy with anti-CTLA-4 and anti-4-1BB antibodies may enhance tumor immunity. However, this treatment is not efficient against all tumors, and it has been suggested that variations in tumor control may reflect differences in the immunogenicity of different tumors. In the present report, we have formally tested this hypothesis. Comparing the efficiency of combination antibody therapy against two antigenically distinct variants of the B16.F10 melanoma cell line, we observed that antibody therapy delayed the growth of a variant expressing an exogenous antigen (P

AB - It has previously been found that combination therapy with anti-CTLA-4 and anti-4-1BB antibodies may enhance tumor immunity. However, this treatment is not efficient against all tumors, and it has been suggested that variations in tumor control may reflect differences in the immunogenicity of different tumors. In the present report, we have formally tested this hypothesis. Comparing the efficiency of combination antibody therapy against two antigenically distinct variants of the B16.F10 melanoma cell line, we observed that antibody therapy delayed the growth of a variant expressing an exogenous antigen (P

U2 - 10.1371/journal.pone.0066081

DO - 10.1371/journal.pone.0066081

M3 - Journal article

C2 - 23785471

VL - 8

JO - PLoS ONE

JF - PLoS ONE

SN - 1932-6203

IS - 6

M1 - e66081

ER -

ID: 46384334